Research
Hormonal
Combined GIPR/GLP1R agonism reduces systemic low-grade inflammation, evidenced by lower hepatic inflammatory markers and circulating adhesion molecules (ICAM-1, VCAM-1).
Dual GIP/GLP-1 therapy may help reduce chronic, low-grade inflammation associated with obesity and cardiovascular risk. This anti-inflammatory effect is part of the mechanism by which these drugs may protect blood vessels.
ModerateSupportsMEDIUM confidence
Combined GIPR/GLP1R agonism, but not the single treatments, attenuated the hepatic gene expression of the macrophage marker F4/80... Combined GIPR/GLP1R agonism lowered the circulating levels of the proatherogenic peptides ICAM-1 and VCAM-1
Why this rating
Pre-clinical data showing clear mechanistic pathways.
Source
Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice
Robin van Eenige et al. · Atherosclerosis · 2023
DOI 10.1016/j.atherosclerosis.2023.03.016
mechanism_only · n=64Cited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Combined GIPR/GLP1R agonism significantly attenuates atherosclerosis severity (shifting lesions from severe to mild) in APOE*3-Leiden.CETP mice, an effect not achieved by single GIPR or GLP1R agonism.Moderate
- Combined GIPR/GLP1R agonism lowers plasma triglyceride levels by increasing VLDL turnover (reduced hepatic VLDL-TG production and increased uptake by adipose tissue and liver).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →